Clinical Research Studies
We do research across every area of cardiovascular care. Our research offers hope for patients, options to discuss with your doctor, and opportunities to make a difference for future patients. See the search below for a list of our active and enrolling clinical research studies and see if you may qualify to participate.
Benefits of Research
Be More Active
Take a more active role in your own health care.
Potential to Unlock More Options
You may gain access to investigational treatments and medications.
Make a Contribution
Help find a new and better way to treat people with your condition.
Search for research studies
MitraClip Expand G4Study Investigator:
Paul Sorajja, MD
About the Study:This primary objective of the EXPAND G4 study is to confirm the safety and performance of the MitraClip G4 System in a post-market setting. Condition:
Valvular Disease (Heart Valve Disease)
|
View Study |
LOWERStudy Investigator:
Thomas Knickelbine, MD
About the Study:This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. Condition:
Other
|
View Study |
EXACTStudy Investigator:
Jay Traverse, MD
About the Study:The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization). Condition:
Angina (Stable/Unstable), Coronary Artery Disease
|
View Study |
ALtFLOStudy Investigator:
Paul Sorajja, MD
About the Study:The purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the Edwards Transcatheter Atrial Shunt System. Condition:
Heart Failure
|
View Study |
AEGIS IIStudy Investigator:
Thomas Knickelbine, MD
About the Study:This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed. Condition:
Other
|
View Study |